301258.SZ Stock Analysis
30
Uncovered
Suzhou Fushilai Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Suzhou Fushilai Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and raw materials for health care products. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2022-03-29. The firm is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and raw materials for health care products. The firm's main products include three series of lipoic acid series, phosphatidylcholine series and carnosine series. The firm mainly conducts its business in domestic and overseas markets such as Europe, America, Japan and South Korea, India and South America.